EMBC (74) CLPT (19) OFIX (47) SI (48) ⌘ Pro Terminal →

Mobia Medical Inc. (MOBI) — RQD Stock Rating Cockpit

$10.58 -6.12% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.44

Mobia Medical Inc. (MOBI) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $375.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MOBI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MOBI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Mobia Medical Inc. (NASDAQ: MOBI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $10.58 (-6.12% 1D, market cap $375.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MOBI compare to EMBC and CLPT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), MOBI carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EMBC (Embecta Corp.) holds a B grade (74/100 RQD, P/E 3.9x, ROIC 35.5%, cap $371.7M) and CLPT (ClearPoint Neuro Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $342.7M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MOBI?

▼

Per MOBI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001489993), Mobia Medical Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $48.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.44 (-1.29%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MOBI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (53/100 Composite)

🔍 WHY MOBI SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (21% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$8.60+2.4% Next Q

Q2 (-2Q)

Grade D$8.81+21.8% Next Q

Q3 (-1Q)

Grade C-$10.73-1.4% Next Q

Current

Grade D+$10.58-0.9% Hist 90D α

Trajectory: D (45) → D+ (53)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MOBI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MOBI currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.03) and Max Pain ($11.11) forces dealer call-delta covering toward $16.05.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MOBI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MOBI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 53%NO 47%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

61.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE35% OF RANGE

L: $8$10.58H: $15

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 20 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on MOBI

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

20/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like MOBI

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MOBI)

✓Walkthrough of MOBI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MOBI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.96%▼ DESCENDING CHANNEL

2026-11-02O $11.79H $11.79L $10.58C $10.58VOL 132.7K

RES: $11.99SUP: $7.21SMA50: $10.03SMA200: $11.43

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MOBI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MOBI Butterfly Map → + Track MOBI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MOBI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MOBI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MOBI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MOBI)

Health Care Rank #258 of 1016 ⚔️ EMBC vs MOBI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MOBI vs. EMBC, CLPT, OFIX, SI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Mobia Medical Inc. (MOBI) ranks #258 by composite RQD confidence (53/100, grade D+) and #488 by equity capitalization ($375.2M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with MOBI at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MOBI ACTIVE Mobia Medical Inc.	D+	53/100	—	—	—	-6.12%	$375.2M	Benchmark Subject
EMBC Embecta Corp.	B	74/100	3.9x	62.6%	35.5%	-4.73%	$371.7M	/embc-vs-mobi →
CLPT ClearPoint Neuro Inc.	E	19/100	—	61.4%	-35.0%	-0.19%	$342.7M	/clpt-vs-mobi →
OFIX Orthofix Medical Inc.	D	47/100	—	68.8%	-12.2%	-11.43%	$417.1M	/ofix-vs-mobi →
SI Shoulder Innovations Inc.	D	48/100	—	76.5%	-16.1%	-6.41%	$425.5M	/si-vs-mobi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001489993

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Mobia Medical Inc. (MOBI) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, MOBI closed FY2025 with $48.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$48.1M	—

3. MOBI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MOBI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MOBI compare to EMBC and CLPT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MOBI?

Where is MOBI trading relative to its 50-day, 200-day, and 52-week technical levels?

MOBI last traded at $10.58 (-6.12% on volume of 143,269 shares), positioning the stock +5.48% above its 50-day simple moving average ($10.03) and -7.44% below its 200-day simple moving average ($11.43). Across its 52-week range of $8.03 to $15.29, MOBI sits at the 35.1% percentile with a 14-day RSI of 61.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($9.26 to $11.90).

MOBI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MOBI stock right now?

Mobia Medical Inc. (MOBI) currently earns a Roarable Rating of D+ (Sell — SELL) with 53/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is MOBI's 12-month price target and RQD AI Jury consensus?

MOBI's 12-month base price target is $10.34 (range $8.07 to $16.05), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MOBI RQD Cockpit MOBI 12M Forecast MOBI Earnings & Move MOBI Dividends & DRIP MOBI Insiders & 13F MOBI Whale Options MOBI Profit Sankey MOBI News & Why

ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MOBI — Mobia Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:16:26Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MOBI scores 53 out of 100, a D+ grade labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 10/20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 11/20 (institutional accumulation and options positioning), Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and the Cash Engine, which for a prospective investor means the rating reflects limited evidence of current cash generation and limited insider-side confirmation. The Balance Sheet pillar is the strongest, indicating a relatively sturdier financial position than the earnings profile alone would suggest. Upside drivers cited in the data are the institutional accumulation signal in the 13F pillar and the bullish liquidity signal in the Butterfly graph; the main valuation tradeoff is that the price of $11.27 cannot be anchored to earnings, since P/E and EPS are not available in source data. Investors should treat the rating as an educational summary of the factors above, not as a recommendation.

Business

Mobia Medical Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry, per the profile. The source data does not describe its products, customers, or revenue model. Revenue for FY 2025 is reported as $0.0M per the SEC financials, so the source data does not show how the company currently makes money. Market capitalization is $0.4B per the profile.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$0.0M	$0.0M	N/A	N/A	$33.6M	N/A

Per the SEC financials, reported revenue, operating income, and net income for FY 2025 are all $0.0M, and gross, operating, and net margins are each 0% per the market data. ROIC is 0% and FCF yield is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9 per the Roarable RQD rating, with Debt/Equity at 0.5. The balance sheet posture is described as cash of $33.6M against debt listed as N/A in the SEC financials.

Recent Catalysts & News Wire Analysis

Earnings date: Multiple headlines report that Mobia Medical will report Q3 2026 / Q3FY26 financial results on November 5, 2026, flagged as a market wire item and a catalyst.
Analyst rating: A MarketBeat headline reports a Buy rating from BTIG Research.
Governance: A Stock Titan headline reports that audit committee appointee Reza Zadno retained his compensation committee seat.
Short interest: A MarketBeat headline reports significant growth in short interest, flagged as a catalyst.
Price target: A MarketBeat headline reports a consensus price target of $20.75 according to analysts.
Butterfly signal: The Butterfly graph carries a bullish Liquidity Tailwind signal with severity 94 and a Macro Tailwind Score of 96/100. Its forensic brief cites a true Net Liquidity of $5,746B, a 4-week rate of change of -0.64%, a z-score of 6.1, a net liquidity elasticity of 6.00x Beta, and a Pearson correlation of r=-0.21. This signal is macro-driven and is not a company-specific fundamental finding.
Risk watch: Price is -4.41% on the day, and short interest growth is reported. Earnings figures are not available in source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE and no butterfly links are recorded, so upstream and downstream dependencies are not available in source data. The only proprietary signal is the macro liquidity tailwind, which links the stock to broad liquidity conditions rather than to specific suppliers or customers. Sector correlations beyond the Health Care classification are not available in source data. The 2nd-order item to watch is whether the liquidity sensitivity (6.00x Beta) persists if net liquidity moves, since the graph itself notes elevated sensitivity to liquidity stabilization.

Analyst View & Smart Money Ownership

Analyst data is listed as NONE in the source data, so the source does not provide a consensus rating or price target from the analyst section. Holder data is listed as NONE, so SEC Form 4 insider, 13F whale, and Congressional trade details are not available in source data. The headline-level references to a BTIG Buy rating and a $20.75 consensus target are reported only in the news wire and are not confirmed by the analyst section.

Open Questions

What products or services generate revenue, given that FY 2025 revenue is reported as $0.0M?
Why are EPS, net income, and FCF reported as zero or N/A, and what is the cash burn trajectory?
What is the basis for the $20.75 consensus target and the BTIG Buy rating cited in news headlines, given that the analyst section is empty?
Who are the institutional holders and insiders behind the accumulation and insider signals, given the holders section is empty?
What are the debt terms behind a Debt/Equity of 0.5 when debt is listed as N/A?

MOBI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Mobia Medical Inc. (MOBI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MOBI Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 9h ago

Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026

Yahoo Finance report covering Mobia Medical Inc. (MOBI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 12h ago

Mobia Medical (NASDAQ:MOBI) Earns Buy Rating from BTIG Research

MarketBeat report covering Mobia Medical Inc. (MOBI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 15h ago

Audit committee appointee Reza Zadno keeps his compensation committee seat at Mobia Medical (MOBI).

Stock Titan report covering Mobia Medical Inc. (MOBI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 18h ago

Mobia Medical, Inc. (NASDAQ:MOBI) Sees Significant Growth in Short Interest

MarketBeat report covering Mobia Medical Inc. (MOBI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE scanx.trade • 21h ago

Mobia Medical to report Q3FY26 results on November 5, 2026

scanx.trade report covering Mobia Medical Inc. (MOBI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Mobia Medical, Inc. (NASDAQ:MOBI) Stock Has Consensus Price Target of $20.75 According to Analysts

MarketBeat report covering Mobia Medical Inc. (MOBI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Top Conexeu Sciences (CNXU) Competitors 2026

MarketBeat report covering Mobia Medical Inc. (MOBI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 13d ago

BTIG Reiterates Buy on Mobia Medical, Maintains $19 Price Target

BTIG analyst Ryan Zimmerman reiterates Mobia Medical (NASDAQ:MOBI) with a Buy and maintains $19 price target.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MOBI Bull vs. Bear Conversation Board — What's Your Call at $10.58?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MOBI 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $12.17 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MOBI (D+ • RQD 53/100) a Buy at $11.27?

Welcome to the MOBI (Mobia Medical Inc.) Roar Pit. Current RQD Composite is 53/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $8.90 (-21.0%)

Spot @ $11.27

Pump the brakes on MOBI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MOBI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Mobia Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $13.97 (+24.0%)

Spot @ $11.27

MOBI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MOBI, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $11.27 (52-wk range $8.03 - $15.29), any beat on forward guidance forces shorts and underweight funds to chase.